Synopsis
Synopsis
0
VMF
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Galantamin
2. Galantamine
3. Galanthamine
4. Galanthamine Hydrobromide
5. Lycoremine
6. Nivalin
7. Nivaline
8. Razadyne
9. Reminyl
1. Galanthamine Hydrobromide
2. 1953-04-4
3. Reminyl
4. Nivalin
5. Nivaline
6. Razadyne
7. Lycoremine Hydrobromide
8. Jilkon Hydrobromide
9. Galanthamine (hydrobromide)
10. Galanthamine Hbr
11. Tamilin
12. 193146-85-9
13. Mj4ptd2vvw
14. 5n4sa4kqx9
15. (-)-galantamine Hydrobromide
16. (+/-)-galantamine Hydrobromide
17. (+/-)-galanthamine Hydrobromide
18. Galantamine Hydrobromide (racemic)
19. Galantamine Hydrobromide, (+/-)-
20. (1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol;hydrobromide
21. (4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol Hydrobromide
22. Razadyne Er
23. Reminyl (tn)
24. (1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azoniatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol;bromide
25. (4as,6r,8as)-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6h-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol Hydrobromide
26. Galanthaminehydrobromide
27. 1953-04-4 (hbr); 1953-04-4 (free Base).
28. (1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^{1,12}.0^{6,17}]heptadeca-6(17),7,9,15-tetraen-14-ol Hydrobromide
29. (4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol Hydrobromide
30. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hydrobromide (1:1), (4ar,6s,8ar)-rel-
31. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hydrobromide (1:1), (4as,6r,8as)-
32. Smr000449267
33. Sr-01000597844
34. Nivaline (pharmaceutical)
35. C17h22brno3
36. Anti-alzheimer
37. Sr-05000001783
38. Nivalin;razadyne
39. Galantamine Hydrobromide [usan]
40. Reminyl Xl
41. Jilcon Hydrobromide
42. Razadyne (tn)
43. Prestwick_236
44. Einecs 217-780-5
45. Galanthamine Hydrobromide From Lycoris Sp.
46. Mfcd00067672
47. Unii-mj4ptd2vvw
48. Unii-5n4sa4kqx9
49. 1953-04-4 Unlabeled
50. Chembl1555
51. Galanthamine-d3 Hydrobromide
52. Mls000758283
53. Mls001401401
54. Galanthamine Hydrobromide,(s)
55. Schembl177993
56. Spectrum1501202
57. Hms1569f18
58. Hms1921p21
59. Hy-a0009
60. Galantamine Hydrobromide (jan/usp)
61. Ac-469
62. Ccg-38829
63. Galantamine Hydrobromide [mi]
64. Galantamine Hydrobromide [usan:usp]
65. S1339
66. Galantamine Hydrobromide [jan]
67. Galanthamine-o-methyl-d3 Hydrobromide
68. Akos007930166
69. Akos015960209
70. Cs-0378
71. Fd10095
72. Galantamine Hydrobromide [hsdb]
73. Nc00061
74. Galantamine Hydrobromide [mart.]
75. Galantamine Hydrobromide [vandf]
76. Galantamine Hydrobromide [usp-rs]
77. Galantamine Hydrobromide [who-dd]
78. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hydrobromide, (4as,6r,8as)-
79. As-12155
80. Gp-37267
81. G0293
82. Galantamine Hydrobromide [orange Book]
83. D02173
84. Galantamine Hydrobromide [ep Monograph]
85. Galantamine Hydrobromide [usp Monograph]
86. Galantamine Hydrobromide Racemic [usp-rs]
87. 953g044
88. A866857
89. A903748
90. R-113675
91. Sr-01000597844-1
92. Sr-01000597844-5
93. Sr-05000001783-3
94. Q47495772
95. Z1558572528
96. Galanthamine Hydrobromide From Lycoris Sp., >=94% (tlc)
97. (4as,6r,8as)-3-methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4ah-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol Hydrobromide
98. (4as,6r,8as)-3-methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4ah-benzo[2,3]benzofuro[4,3-cd]azepin-6-olhydrobromide
99. (4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, Hydrobromide
100. (4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-d3-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol Hydrobromide
101. 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol Hydrobromide
102. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hbr (1:1), (4as,6r,8as)-
103. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hbr, (4as,6r,8as)-
104. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hydrobromide, (4a.alpha.,6.beta.,8ar*)-
105. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hydrobromide, (4aalpha,6beta,8ar*)-
1. Galantamine
2. Galanthamine Hydrobromide
3. Lycoremin
4. Lycoremine
5. Nivalin
6. Razadyne
7. Reminyl
8. Galanthamine
Molecular Weight | 368.3 g/mol |
---|---|
Molecular Formula | C17H22BrNO3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 1 |
Exact Mass | 367.07831 g/mol |
Monoisotopic Mass | 367.07831 g/mol |
Topological Polar Surface Area | 41.9 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 440 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Galantamine hydrobromide |
PubMed Health | Galantamine (By mouth) |
Drug Classes | Central Nervous System Agent |
Drug Label | Galantamine hydrobromide is a reversible, competitive acetylcholinesterase inhibitor. Galantamine hydrobromide is known chemically as (4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro [3a,3,2-ef][2]benzazepin-6-ol hydrobromide.... |
Active Ingredient | Galantamine hydrobromide |
Dosage Form | Tablet; Capsule, extended release; Solution |
Route | oral; Oral |
Strength | eq 4mg base; 8mg; eq 12mg base; 4mg; 4mg/ml; 12mg; eq 16mg base; eq 24mg base; eq 8mg base |
Market Status | Tentative Approval; Prescription |
Company | Ranbaxy; Apotex; Aurobindo Pharma; Sun Pharm Inds; Sandoz; Sun Pharma Global; Roxane; Watson Labs; Teva Pharms; Zydus Pharms Usa; Dr Reddys Labs; Mylan; Impax Labs; Barr |
2 of 4 | |
---|---|
Drug Name | Razadyne |
Drug Label | RAZADYNE ER/RAZADYNE (galantamine hydrobromide) is galantamine hydrobromide, a reversible, competitive acetylcholinesterase inhibitor. Galantamine hydrobromide is known chemically as (4aS ,6R,8aS )-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H... |
Active Ingredient | Galantamine hydrobromide |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | eq 4mg base; eq 12mg base; 4mg/ml; eq 8mg base |
Market Status | Prescription |
Company | Janssen Pharms |
3 of 4 | |
---|---|
Drug Name | Galantamine hydrobromide |
PubMed Health | Galantamine (By mouth) |
Drug Classes | Central Nervous System Agent |
Drug Label | Galantamine hydrobromide is a reversible, competitive acetylcholinesterase inhibitor. Galantamine hydrobromide is known chemically as (4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro [3a,3,2-ef][2]benzazepin-6-ol hydrobromide.... |
Active Ingredient | Galantamine hydrobromide |
Dosage Form | Tablet; Capsule, extended release; Solution |
Route | oral; Oral |
Strength | eq 4mg base; 8mg; eq 12mg base; 4mg; 4mg/ml; 12mg; eq 16mg base; eq 24mg base; eq 8mg base |
Market Status | Tentative Approval; Prescription |
Company | Ranbaxy; Apotex; Aurobindo Pharma; Sun Pharm Inds; Sandoz; Sun Pharma Global; Roxane; Watson Labs; Teva Pharms; Zydus Pharms Usa; Dr Reddys Labs; Mylan; Impax Labs; Barr |
4 of 4 | |
---|---|
Drug Name | Razadyne |
Drug Label | RAZADYNE ER/RAZADYNE (galantamine hydrobromide) is galantamine hydrobromide, a reversible, competitive acetylcholinesterase inhibitor. Galantamine hydrobromide is known chemically as (4aS ,6R,8aS )-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H... |
Active Ingredient | Galantamine hydrobromide |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | eq 4mg base; eq 12mg base; 4mg/ml; eq 8mg base |
Market Status | Prescription |
Company | Janssen Pharms |
Nootropic Agents
Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)
Cholinesterase Inhibitors
Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)
Parasympathomimetics
Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Complete
Rev. Date : 2014-12-05
Pay. Date : 2012-11-08
DMF Number : 18112
Submission : 2005-02-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18152
Submission : 2005-03-03
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18045
Submission : 2005-01-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15384
Submission : 2001-05-08
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14425
Submission : 1999-09-29
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-08-24
Pay. Date : 2015-08-17
DMF Number : 17863
Submission : 2004-12-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18114
Submission : 2005-02-22
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17967
Submission : 2005-01-03
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17972
Submission : 2005-01-05
Status : Active
Type : II
Galantamine Hydrobromide, Produced By A Syntheti...
Certificate Number : CEP 2009-316 - Rev 03
Status : Valid
Issue Date : 2024-10-30
Type : Chemical
Substance Number : 2366
Galantamine Hydrobromide, Isolated From Natural ...
Certificate Number : R1-CEP 2011-288 - Rev 01
Status : Valid
Issue Date : 2020-11-19
Type : Chemical
Substance Number : 2366
Galantamine Hydrobromide, Produced By A Syntheti...
Certificate Number : R1-CEP 2012-248 - Rev 01
Status : Valid
Issue Date : 2021-11-19
Type : Chemical
Substance Number : 2366
Galantamine Hydrobromide, Produced By A Syntheti...
Certificate Number : R1-CEP 2011-123 - Rev 02
Status : Valid
Issue Date : 2022-08-12
Type : Chemical
Substance Number : 2366
Galantamine Hydrobromide, Produced By A Syntheti...
Certificate Number : CEP 2023-389 - Rev 00
Status : Valid
Issue Date : 2024-06-19
Type : Chemical
Substance Number : 2366
Galantamine Hydrobromide, Produced By A Syntheti...
Certificate Number : R1-CEP 2012-328 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2019-03-07
Type : Chemical
Substance Number : 2366
Galantamine Hydrobromide, Produced By A Syntheti...
Certificate Number : CEP 2011-011 - Rev 02
Status : Valid
Issue Date : 2024-10-21
Type : Chemical
Substance Number : 2366
Galantamine Hydrobromide, Isolated From Natural ...
Certificate Number : CEP 2011-053 - Rev 03
Status : Valid
Issue Date : 2025-01-13
Type : Chemical
Substance Number : 2366
Galantamine hydrobromide "Apitoria"
Registration Number : 306MF10088
Registrant's Address : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad, Telangana, INDIA.
Initial Date of Registration : 2024-07-03
Latest Date of Registration : 2024-07-03
Registration Number : 231MF10054
Registrant's Address : 1A, Sector 16A, Noida 201 301, Uttar Pradesh, India
Initial Date of Registration : 2019-02-21
Latest Date of Registration : 2019-02-21
Registration Number : 230MF10065
Registrant's Address : No. 1, Nan-Ke 8th Road, Shan-Hua, Tainan 741014, Taiwan
Initial Date of Registration : 2018-05-15
Latest Date of Registration : 2022-01-26
Galantamine hydrobromide (Teva)
Registration Number : 231MF10027
Registrant's Address : Ostravska 305/29, Komarov, 747 70 Opava, Czech Republic
Initial Date of Registration : 2019-02-05
Latest Date of Registration : 2019-02-05
Galantamine Hydrobromide Ph.Eur
Date of Issue : 2022-06-07
Valid Till : 2025-06-25
Written Confirmation Number : WC-0023
Address of the Firm : Survey no. 52,53,58,59,61 to 78,127&128, Pydibhimanvaram Village &Sy.No. 1,2,4t0...
Registrant Name : Lee Sung International Co., Ltd.
Registration Date : 2021-10-15
Registration Number : 20211015-209-J-1014
Manufacturer Name : Apitoria Pharma Private Limi...
Manufacturer Address : Sy No's. 52, 53, 58, 59, 61 to 78, 127 & 128, Pydibhimavaram Village & Sy No's. 1, 2,...
Registrant Name : Sungwoo Chemical Co., Ltd.
Registration Date : 2023-03-15
Registration Number : 20211015-209-J-1014(1)
Manufacturer Name : Aurobindo Pharma Limited (Un...
Manufacturer Address : Unit-XI, Survey No, 1/22, 2/1 to 5,6 to 18, 61 to 69, Pydibhimavaram Village, Ranasth...
Registrant Name : Clinizen Korea Co., Ltd.
Registration Date : 2021-06-10
Registration Number : 20210610-209-J-538
Manufacturer Name : Janssen Pharmaceutica NV
Manufacturer Address : Jassen Pharmaceuticalaan 3, Geel, 2440, Belgium
Registrant Name : Hyundai Pharmaceutical Co., Ltd.
Registration Date : 2021-10-12
Registration Number : 20211012-209-J-1119
Manufacturer Name : ScinoPharm Taiwan, Ltd.
Manufacturer Address : No. 1, Nan-ke 8th Road, Shan-Hua, Tainan 741014, Taiwan
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2021-05-10
Registration Number : 20210510-209-J-776
Manufacturer Name : Teva Czech Industries sro
Manufacturer Address : Ostravska 305/29, Komarov 747 70 Opava, Czech Republic.
NDC Package Code : 65862-487
Start Marketing Date : 2024-01-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 12578-890
Start Marketing Date : 2001-11-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65372-1138
Start Marketing Date : 2008-11-28
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65129-1113
Start Marketing Date : 2004-04-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65129-1332
Start Marketing Date : 2013-09-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 47848-023
Start Marketing Date : 2022-01-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (100kg/100kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 55111-081
Start Marketing Date : 2005-01-20
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Capital Farma, a leading European pharmaceutical company focusing on the development & distribution of niche APIs & Pharma Services.
About the Company : Capital Farma offers a comprehensive range of pharmaceutical solutions. Our API offering includes active ingredients sourced exclusively from top European manufacturers, ensuring t...
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
About the Company : MINAKEM is a cGMP custom manufacturer of small molecule API, HPAPI and steroids. All development and manufacturing activities are supported by highly skilled R&D teams, supported b...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
About the Company : Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company comme...
About the Company : Credo Life one place for credibility, commitment, quality and delivery on time. Promoted by a dynamic team of techno-commercial professionals with decades of experience in the Phar...
About the Company : Pellets Pharma Limited is a fast growing organization established by a team of professionals with over decades of experience in the pharmaceutical industry with specific reference ...
About the Company : Polaris AI Pharma is a dynamic company specializing in innovative pharmaceutical solutions. Leveraging cutting-edge AI technology, it focuses on drug discovery, development, and op...
About the Company : Ravoos Laboratories Limited is one of the fastest growing pharmaceutical company located in Hyderabad, South India. Ravoos Laboratories Limited (RLL) made modest foray in the ye...
About the Company : ScinoPharm Taiwan Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a w...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
RJx-01 is a combination of galantamine and metformin, works by inhibiting AChE and acting as an allosteric modulator of nAChRs, being investigated for COPD-related muscle weakness.
Lead Product(s): Galantamine Hydrobromide,Metformin
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RJx-01
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: National Institute for Health and Care Research
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 19, 2025
Lead Product(s) : Galantamine Hydrobromide,Metformin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : National Institute for Health and Care Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Rejuvenate Doses First Patient in Phase 2 Trial on COPD Muscle Weakness & Sarcopenia
Details : RJx-01 is a combination of galantamine and metformin, works by inhibiting AChE and acting as an allosteric modulator of nAChRs, being investigated for COPD-related muscle weakness.
Product Name : RJx-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 19, 2025
Details:
Essential Pharma has acquired rights to Reminyl (galantamine), a cholinesterase inhibitor, for the EEA, Thailand, South Korea, and other markets, excluding the UK and Japan.
Lead Product(s): Galantamine Hydrobromide
Therapeutic Area: Neurology Brand Name: Reminyl
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Essential Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 17, 2024
Lead Product(s) : Galantamine Hydrobromide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Essential Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Essential Pharma Acquires Reminyl® (galantamine hydrobromide) Capsules
Details : Essential Pharma has acquired rights to Reminyl (galantamine), a cholinesterase inhibitor, for the EEA, Thailand, South Korea, and other markets, excluding the UK and Japan.
Product Name : Reminyl
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 17, 2024
Details:
RJx-01, a novel combination drug comprising galantamine and metformin, demonstrated positive results in 42 elderly male subjects with disuse-induced muscle atrophy.
Lead Product(s): Galantamine Hydrobromide,Metformin
Therapeutic Area: Musculoskeletal Brand Name: RJx-01
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2023
Lead Product(s) : Galantamine Hydrobromide,Metformin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RJx-01, a novel combination drug comprising galantamine and metformin, demonstrated positive results in 42 elderly male subjects with disuse-induced muscle atrophy.
Product Name : RJx-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2023
Details:
RJx-01 is a novel combination of known drugs, there are already extensive safety data available for the constituent compounds. Results will be based on a combination of classic and hi-tech assessment techniques, including data from wearable health tech devices.
Lead Product(s): Galantamine Hydrobromide
Therapeutic Area: Musculoskeletal Brand Name: RJx-01
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 29, 2022
Lead Product(s) : Galantamine Hydrobromide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rejuvenate Biomed Started a Groundbreaking Clinical Trial and Expands for Future Growth
Details : RJx-01 is a novel combination of known drugs, there are already extensive safety data available for the constituent compounds. Results will be based on a combination of classic and hi-tech assessment techniques, including data from wearable health tech d...
Product Name : RJx-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2022
CAS Number : 510-77-0
End Use API : Galantamine Hydrobromide
About The Company : Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in...
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Galantamin SR Zentiva
Dosage Form : Ret Kaps
Dosage Strength : 16mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Galantamin SR Zentiva
Dosage Form : Ret Kaps
Dosage Strength : 24mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Galantamin SR Zentiva
Dosage Form : Ret Kaps
Dosage Strength : 8mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : Galantamine Orion
Dosage Form : PROLONGED-RELEASE CAPSULE, HARD
Dosage Strength : 8 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Galantamine Orion
Dosage Form : PROLONGED-RELEASE CAPSULE, HARD
Dosage Strength : 16 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Galantamine Orion
Dosage Form : PROLONGED-RELEASE CAPSULE, HARD
Dosage Strength : 24 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Sustain Release Pellet
Dosage Strength : 8%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsule
Dosage Strength : 8MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsule
Dosage Strength : 16MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsule
Dosage Strength : 24MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
28
PharmaCompass offers a list of Galantamine Hydrobromide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Galantamine Hydrobromide manufacturer or Galantamine Hydrobromide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Galantamine Hydrobromide manufacturer or Galantamine Hydrobromide supplier.
PharmaCompass also assists you with knowing the Galantamine Hydrobromide API Price utilized in the formulation of products. Galantamine Hydrobromide API Price is not always fixed or binding as the Galantamine Hydrobromide Price is obtained through a variety of data sources. The Galantamine Hydrobromide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Reminyl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Reminyl, including repackagers and relabelers. The FDA regulates Reminyl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Reminyl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Reminyl manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Reminyl supplier is an individual or a company that provides Reminyl active pharmaceutical ingredient (API) or Reminyl finished formulations upon request. The Reminyl suppliers may include Reminyl API manufacturers, exporters, distributors and traders.
click here to find a list of Reminyl suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Reminyl DMF (Drug Master File) is a document detailing the whole manufacturing process of Reminyl active pharmaceutical ingredient (API) in detail. Different forms of Reminyl DMFs exist exist since differing nations have different regulations, such as Reminyl USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Reminyl DMF submitted to regulatory agencies in the US is known as a USDMF. Reminyl USDMF includes data on Reminyl's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Reminyl USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Reminyl suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Reminyl Drug Master File in Japan (Reminyl JDMF) empowers Reminyl API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Reminyl JDMF during the approval evaluation for pharmaceutical products. At the time of Reminyl JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Reminyl suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Reminyl Drug Master File in Korea (Reminyl KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Reminyl. The MFDS reviews the Reminyl KDMF as part of the drug registration process and uses the information provided in the Reminyl KDMF to evaluate the safety and efficacy of the drug.
After submitting a Reminyl KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Reminyl API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Reminyl suppliers with KDMF on PharmaCompass.
A Reminyl CEP of the European Pharmacopoeia monograph is often referred to as a Reminyl Certificate of Suitability (COS). The purpose of a Reminyl CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Reminyl EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Reminyl to their clients by showing that a Reminyl CEP has been issued for it. The manufacturer submits a Reminyl CEP (COS) as part of the market authorization procedure, and it takes on the role of a Reminyl CEP holder for the record. Additionally, the data presented in the Reminyl CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Reminyl DMF.
A Reminyl CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Reminyl CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Reminyl suppliers with CEP (COS) on PharmaCompass.
A Reminyl written confirmation (Reminyl WC) is an official document issued by a regulatory agency to a Reminyl manufacturer, verifying that the manufacturing facility of a Reminyl active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Reminyl APIs or Reminyl finished pharmaceutical products to another nation, regulatory agencies frequently require a Reminyl WC (written confirmation) as part of the regulatory process.
click here to find a list of Reminyl suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Reminyl as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Reminyl API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Reminyl as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Reminyl and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Reminyl NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Reminyl suppliers with NDC on PharmaCompass.
Reminyl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Reminyl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Reminyl GMP manufacturer or Reminyl GMP API supplier for your needs.
A Reminyl CoA (Certificate of Analysis) is a formal document that attests to Reminyl's compliance with Reminyl specifications and serves as a tool for batch-level quality control.
Reminyl CoA mostly includes findings from lab analyses of a specific batch. For each Reminyl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Reminyl may be tested according to a variety of international standards, such as European Pharmacopoeia (Reminyl EP), Reminyl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Reminyl USP).